CHARLOTTESVILLE, Va., Oct. 26 -- The University of Virginia issued the following news release:
A personalized melanoma vaccine, called intismeran, could mark a major advance in cancer treatment. Last week, pharmaceutical companies Merck and Moderna announced clinical trial results showing the vaccine, combined with immunotherapy, reduced the risk of cancer returning or death by 42% compared with immunotherapy alone.
Dr. Craig Slingluff, a UVA Health researcher who has spent decades developing cancer vaccines, says the findings offer new hope for helping more patients live longer and potentially curing some cancers.
He spoke with UVA Today about how the vaccine works, what it means for patients and why the future of cancer treatment looks...